Celecoxib and Breast Cancer Risk
Author Information
Author(s): Qin Wenyi, Zhu Weizhu, Hewett John E, Rottinghaus George, Chen Yin-Chieh, Flynn John T, Kliethermes Beth, Mannello Ferdinando, Sauter Edward R
Primary Institution: University of North Dakota
Hypothesis
Does celecoxib affect the expression of uPA, PAI-1, and PGE2 in women at increased risk of breast cancer?
Conclusion
Celecoxib treatment may upregulate uPA and downregulate PAI-1 and PGE2, potentially offering a cancer preventive effect.
Supporting Evidence
- Celecoxib concentrations were higher in women taking 400 mg compared to 200 mg.
- In postmenopausal women, uPA concentrations increased with the higher dose of celecoxib.
- PAI-1 and PGE2 levels decreased in response to higher celecoxib doses.
Takeaway
This study looked at how a medicine called celecoxib might help women at risk for breast cancer by changing certain proteins in their bodies.
Methodology
Women at increased breast cancer risk took celecoxib for 14 days, and samples of nipple aspirate fluid and plasma were analyzed for uPA, PAI-1, and PGE2 levels.
Potential Biases
Individual differences in celecoxib metabolism may affect results.
Limitations
Sample size may have limited the ability to detect significant effects.
Participant Demographics
Women aged 18 and older at increased risk for breast cancer, including premenopausal and postmenopausal.
Statistical Information
P-Value
0.0048
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website